Prevalence and risk factor of Chloroquine maculopathy in patients at Ang thong hospital
Keywords:
Chloroquine maculopathy, maculopathy, chloroquineAbstract
We performed a retrospective study to evaluate prevalence and risk factors of chloroquine maculopathy in Angthong hospital. Data were collected from medical record review to identify patients taking chloroquine who were screened for toxic effects from January 1, 2000 through December 31, 2019.
From 185 patients, 93% were female with mean age 57 years, median of duration of treatment were 1,246(651, 2,261) days and mean of daily doses were 4.56±0.98 mg. Forty patients developed maculopathy after using chloroquine. Duration of treatment more than 10 years and daily doses more than 4.6 mg/realBW/day were significant risk factor.
The prevalence of chloroquine maculopathy in Angthong hospital was 21.62%. Eye screening should be done within 8 months because we found the earliest patient with maculopathy after using chloroquine 258 days. Annually screening should be performed to prevent visual loss. Daily dose more than 4.6 mg/realBW/day and duration of treatment more than 10 years were significant risk factor for maculopathy.
Downloads
References
Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol. 1997; 36:799–805.
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Cri Care. 2020.
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-73.
Devaux C, Rolain J, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19. Int J Antimicrob Agents. 2020;55(5):105938.
Mavrikakis M, Papazoglou S, Sfikakis PP, Vaiopoulos G, Rougas K. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis. 1996; 55(3):187-9.
Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: A report by the American Academy of Ophthalmology. Ophthalmology. 2002; 109:1377–82.
Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol 2014; 132:1105–12.
Kellner S, Weinitz S, Farmand G, Kellner U. Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol 2014; 98:200–6.
Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011; 118:415–22.
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386-94.
Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong ST, Janwitayanujit S, et al. Ocular toxicity of chloroquine among Thai patients. Int J Dermatol. 1999; 38:934–7.
Chiowchanwisawakit P, Nilganuwong S, Srinonprasert V, Boonprasert R, Chandranipapongse W, Chatsiricharoenkul S, et al. Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy. Int J Rheum Dis. 2013; 16:47–55.
Srikua U, Aui-Aree N. Timing of chloroquine and hydroxychloroquine screening. Thai J Ophthalmol. 2008; 22:61–8.
Leecharoen S, Wangkaew S, Louthrenoo W. Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma. J Med Assoc Thai. 2007; 90:52–8.
Thongsiw S. Chloroquine maculopathy in Chiang Rai Regional Hospital. Lampang Med J. 2010; 31:98–103.
Suansilpong A, Uaratanawong S. Accuracy of Amsler grid in screening for chloroquine retinopathy. J Med Assoc Thai. 2010; 93:462–6.
Samsen P, Ruangvoravate N, Chiemchaisri Y, Parivisutti L. Chloroquine keratopathy. Thai J Ophthalmol. 1995;9:167–73.
Rujiwetpongstorn J. Incidence and Factors Associated with Chloroquine Maculopathy in Patients Treated at Lamphun Hospital. Lanna Public Health Journal 2015;11:39-45.
Tangtavorn N, Yospaiboon Y, Ratanapakorn T, Sinawat S, Sanguansak T, Bhoomibunchoo C et al. Incidence of and risk factors for chloroquine and hydroxychloroquine retinopathy in Thai rheumatologic patients. Clin Ophthalmol. 2016;10:2179-85.
Elman A, Gullberg R, Nisson E, Rendahl I, wachtmeister L. Chloroquine retinopathy in patients with rheumatoid arthritis. Scand J Rhematol. 1976;5(3):161-6.
Kunavisarut P, Chavengsaksongkram P, Rothova A, Pathanapitoo K. Screening for chloroquine maculopathy in populations with uncertain reliability in outcomes of automatic visual field testing. Indian J Ophthalmol. 2016; 64(10):710-4.
Melles R.B., Marmor M.F.: The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014; 132:1453-60.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Singburi Hospital
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The published articles are copyrighted by Singburi Hospital.
The statements appearing in each article in this academic journal are the personal opinions of each author and are not related in any way to Singburi Hospital or other hospital personnel. Each author is solely responsible for all contents of their article. If there are any errors, each author alone will be responsible for their own article.
